company background image
VTGN

VistaGen Therapeutics NasdaqCM:VTGN Stock Report

Last Price

US$0.13

Market Cap

US$27.1m

7D

-4.9%

1Y

-92.7%

Updated

06 Dec, 2022

Data

Company Financials +
VTGN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VTGN Stock Overview

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).

VistaGen Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for VistaGen Therapeutics
Historical stock prices
Current Share PriceUS$0.13
52 Week HighUS$2.11
52 Week LowUS$0.077
Beta0.50
1 Month Change5.81%
3 Month Change-20.49%
1 Year Change-92.71%
3 Year Change-78.84%
5 Year Change-88.88%
Change since IPO-99.73%

Recent News & Updates

Recent updates

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Shareholder Returns

VTGNUS BiotechsUS Market
7D-4.9%1.9%-0.4%
1Y-92.7%-11.2%-20.6%

Return vs Industry: VTGN underperformed the US Biotechs industry which returned -6.5% over the past year.

Return vs Market: VTGN underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is VTGN's price volatile compared to industry and market?
VTGN volatility
VTGN Average Weekly Movement15.2%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: VTGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: VTGN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199834Shawn Singhhttps://www.vistagen.com

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders.

VistaGen Therapeutics, Inc. Fundamentals Summary

How do VistaGen Therapeutics's earnings and revenue compare to its market cap?
VTGN fundamental statistics
Market CapUS$27.14m
Earnings (TTM)-US$64.69m
Revenue (TTM)n/a

-147.4x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VTGN income statement (TTM)
Revenue-US$185.70k
Cost of RevenueUS$0
Gross Profit-US$185.70k
Other ExpensesUS$64.51m
Earnings-US$64.69m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.31
Gross Margin100.00%
Net Profit Margin34,836.35%
Debt/Equity Ratio2.5%

How did VTGN perform over the long term?

See historical performance and comparison